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ABSTRACT

Prostasin protein has been found to be a useful marker for
determination of the invasiveness of and as a means to treat
human carcinomas. Using RT-PCR and western blot
analyses, prostasin protein and mRNA expression were
found in normal human prostate epithelial cells and the
human prostate cancer cell line LNCaP, but not in the highly
invasive human prostate cancer cell lines DU-145 and PC-3.
Imunohistochemistry studies of human prostate cancer
specimens revealed a down-regulation of prostasin in highgrade tumors. Using RT-PCR and western blot analyses,
prostasin protein and mRNA expression were found in a
non-invasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231 and
MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast
cancer cell line, MDA-MB-453, was shown to express
prostasin mRNA but not prostasin protein. Transfection of
DU-145 and PC-3 cells with a full-length human prostasin
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a full-length
human prostasin cDNA restored prostasin expression and
reduced the in vitro invasiveness by 50% for either cell line.
4 Claims, 6 Drawing Sheets
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:211-22, 1992), for which no effective treatment exists
(Yagoda A Petrylak D. Cytotoxic chemotherapy for
TREATING INVASIVE CARCINOMAS
advanced hormone-resistant prostate cancer. [Review] [ 63
refs] Cancer. 71(3 Suppl): 1098-109, 1993 and Petrylak,
This is a divisional of application Ser. No. 09/755,811
5 1993). Of the remaining 50% cases, 1/3 (-50,000) are diagfiled Jan. 5, 2001, now U.S. Pat. No. 6,569,684.
nosed as organ-confined but micrometastasis may be
This invention relates to prostasin and its use in the
present. The final group of patients (-100,000) have truly
diagnosis and treatment of prostate and breast cancers, and
organ-confined prostate cancer and can be cured by radical
claims the priority to U.S. Provisional Application Serial
prostatectomy (Sgrignoli AR Walsh P C. Steinberg G D.
No. 60/174,801 filed Jan. 6, 2000 and was supported in part
by Department of Defense Prostate Cancer Research Grant 10 Steiner M S. Epstein J I. Prognostic factors in men with
stage Dl prostate cancer: identification of patients less likely
DAMD17-98-l-8590, and in part by grants to principal
to have prolonged survival after radical prostatectomy [see
investigator K. X. CHAI from the Florida Hospital Gala
comments]. Journal of Urology. 152(4): 1077-81, 1994;
Endowed Program for Oncologic Research.
Zincke H. Oesterling J E. Blute ML. Bergstralh E J. Myers
BACKGROUND AND PRIOR ART
15 R P. Barrett D M. long term (15 years) results after radical
prostatectomy for clinically localized (stage T2c or lower)
For men in the U.S., prostate cancer is the most comprostate cancer [see comments]. Journal of Urology. 152(5
monly diagnosed cancer, and the second leading cause of
Pt 2): 1850-7, 1994) or left untreated (watchful waiting)
cancer-related death (Greenlee R T, Murray T. Bolden S.
without the risk of life-threatening or life-altering. For the
Wingo PA Cancer statistics, 1999. Ca: a Cancer Journal for
Clinicians 2000:50:7-33). Prostate cancers originate as 20 patients with non-organ-confined prostate cancers
(discovered via either biopsy or surgery), undergoing syslocalized lesions; some of these localized lesions will
temic treatment early is essential to the management of their
progress to become invasive, migratory and metastatic. Our
cancer (Yagoda A Petrylak D. Cytotixic chemotherapy for
current understanding of the mechanisms of the prostate
advanced hormone-resistant prostate cancer [Review] [ 63
cancer invasion process, however, is poor. Our ability to
predict the acquisition of invasive potentials by a prostate 25 refs] Cancer. 71(3 Suppl): 1098-109, 1993). Consequently,
it will be ideal, both medically and economically, if one
cancer is limited.
could precisely predict upon early pathological examination
The mechanisms leading to the development of a prostate
of the tumor, which group of patients will have truly
cancer are complex. Currently, it is believed to be the result
organ-confined disease versus which group will have invaof multiple transformation steps from normal prostate glandular cells (Carter H B. Piantadosi S. Isaacs J T. Clinical 30 sive prostate cancer.
Clinical staging of prostate cancer generally depends on
evidence for and implications of the multistep development
the results of three tests that are performed in the following
of prostate cancer. Journal of Urology. 143(4):742-6, 1990).
order: a PSA (prostate-specific antigen) blood test as a
The initial steps result in what are described as prostatic
screening method; DRE (digital rectal examination) for an
interepithelial neoplastic (PIN) lesions (Isaacs J T. Molecular markers for prostate cancer metastasis. Developing diag- 35 initial indication of palpable disease; and, a biopsy to obtain
samples for histological examination. Prostate cancers,
nostic methods for predicting the aggressiveness of prostate
removed either via biopsy or surgery, are graded histologicancer. [Review] [92 refs] American Journal of Pathology.
cally by the system of Gleason. (Gleason D F. Classification
150(5):1511-21, 1997). These PIN lesions may then typiof prostatic carcinomas. Cancer Chemotherapy Reportscally have three different fates based on an assessment of
their impact to the patient. The PIN lesions can remain as 40 Part 1. 50(3):125-8, 1966), which is an evaluation of how
aggressive and how poorly-differentiated the prostate cansuch, not producing histologically detectable prostate
cers are. The aggressiveness of prostate tumors: of low
cancer, or further transform into histologically detectable
Gleason scores ( <5) is limited; of high Gleason scores
prostate cancer. Most of the histologically detectable pros(8-10) are highly aggressive; but, for the intermediate
tate cancers will be asymptomatic in the patient and remain
non-manifest clinically as many are discovered post-mortem 45 Gleason-score (5-7) prostate cancers (76% of prostate
tumors), the accuracy of predicting their aggressiveness is
(Carter H Coffey D. Prostate Cancer: the magnitude of the
poor (Gleason D F. Mellinger GT. Prediction of prognosis
problem in the United States. In a Multidisciplinary Analysis
for prostatic adenocarcinoma by combined histological
of Controversies in the Management of Prostate Cancer.
grading and clinical staging. Journal of Urology. 111(1)
(Eds. Coffey D. Resnick M. Door R. et al.), ppl-9, Plenum
Press, 1988; Carter H B Piantadosi S. Issacs J T. Clinical 50 :58-64, 1974). Thus, the ability to accurately determine the
aggressiveness of these intermediate Gleason-score prostate
evidence for implications of the multistep development of
tumors has remained as a practical challenge to, and a
prostate cancer. Journal of Urology. 143(4):742-6, 1990;
primary goal for, prostate cancer research (Isaacs J T.
Scardino P T. Weaver R. Hudson M A Early detection of
Molecular markers for prostate cancer metastasis. Developprostate cancer. [Review] [102 refs] Human Pathology.
23(3):211-22, 1999). Prostate cancers are diagnosed clini- 55 ing diagnostic methods for predicting the aggressiveness of
prostate cancer. [Review] [92 refs] American Journal of
cally by an estimate of size and location using the TNM
Pathology. 150(5): 1511-21, 1997). Especially with regard to
staging system (Denis L J. Staging and prognosis of prostate
the number of patients (150,000) facing a decision of
cancer. European Urology. 24 Suppl 2:13-8, 1993), and by
whether to undergo systemic treatment, the most urgent
pathological staging based on an examination of the histology of the removed prostate via either biopsy or prostatec- 60 demand in prostate cancer care is the development of
methods to enhance our ability to accurately predict the
tomy using a system by D. F. Gleason, (Gleason D F.
aggressiveness of the tumors with Gleason scores of 5-7.
Classification of prostatic carcinomas. Cancer Chemotherapy Reports-Part 1. 50(3):125-8, 1966). About 50% of
It is now commonly believed that cancers occur via
multiple transformation steps by accumulating mutations in
prostate cancer cases receiving treatment are diagnosed
clinically as advanced, or, non-organ-confined (Scardino P 65 three classes of genes: proto-oncogenes (Park M. OncoT. Weaver R. Hudson M A Early detection of prostate
genes. In The Genetic Basis of Human Cancer (Eds. Vogelcancer. [Review] [102 refs] Human Pathology. 23(3)
stein B and Kinzler KW). pp205-28. McGraw-Hill Health
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Professions Divisions, 1998); tumor-suppressor genes
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A
(Knuutila S. Aalto Y. Bjorkqvist AM. EL-Rifai W. Hemmer
Decreased E-cadherin expression is associated with poor
S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S. Larramendy M
prognosis in patients with prostate cancer. Cancer Research.
L. Lushnikova T. Manni 0. Pere H. Tapper J. Tarkkanen M.
54(14):3929-33, 1994); ~ic integrin (Fornaro M. Tallini G.
Varis A Wasenius V M. Wolf M. Zhu Y. DNA copy number 5 Bofetiado CJ. Bosari S. Languino LR. Down-regulation of
losses in human neoplasms. [Review] [197 refs] American
~lC integrin, an inhibitor of cell proliferation, in prostate
Journal of Pathology. 155(3):683-94, 1999); and, DNA
carcinoma. American Journal of Pathology. 149(3):765-73,
repair genes (Knuutila S. Aslto Y. Bjorkqvit AM. EL-Rifai
1996 Fornaro M. Manzotti M. Tallini G. Slear A E. Bosari
W. Hemmer S. Huhta T. Kettunen E. Kiuru-Kuhlefelt S.
S. Ruoslahti E. Languino LR. ~lC integrin in epithelial cells
Larramedy ML. Lushnikova T. Manni 0. Pere H. Tapper J. 10 correlates with a nonproliferative phenotype: forced expresTarkkanen M. VarisA. Wasenius V M. Wolf M. Zhu Y. DNA
sion of ~lC inhibits prostate epithelial cell proliferation.
copy number losses in human neoplasms. [Review] [197
American Journal of Pathology. 153(4):1079-87, 1998; p27
refs] American Journal of Pathology. 155(3):683-94, 1999).
(kipl) (Tsihlias J. Kapusta LR. DeBoer G. Morava-Protzner
The histological prostate cancers for which the prediction of
I. Zbieranowski I. Bhattachaya N. Catzavelos G C. Klotz L
clinical aggressiveness is difficult (those with the interme- 15 H. Slingerland JM. Loss of cyclin-dependent kinase inhibidiate Gleason scores 5-7) probably have not gone through
tor p27Kipi is a novel prognostic factor in localized human
the necessary "multi-step" transformation to acquire the
prostate adenocarcinoma. Cancer Research. 58(3):542-8,
potentials to behave aggressively (as would the high-grade
1998); and CD44 (Lou W. Krill D. Dhir R. Becich M J. Dong
cancers). This notion was supported by studies comparing
J T. Frierson H F Jr. Isaacs W B. Isaacs J T. Gao A C.
the course of prostate cancer development among men in 20 Methylation of the CD44 metastasis suppressor gene in
Japan and in the U.S., and Japanese men who migrated to the
human prostrate cancer. Cancer Research. 59(10):2329-31,
U.S. (Carter H B. Piantadosi S. Isaacs J T. Clinical evidence
1999). By using the method of immunohistochemistry, these
for and implications of the multistep development of prosgenes were found to be down-regulated in prostate cancer.
tate cancer. Journal of Urology, 1990; Haenszel W. Kurihara
KAI's down regulation is a potential predictor of metastasis
M. Studies of Japanese Migrants. I. Mortality form cancer 25 (Dong, et al., 1996: Ueda et al., 1996). While E-cadherin's
and other diseases among Japanese in the United States.
down regulation is strongly correlated to higher Gleason
Journal of the National Cancer Institute. 40(1):43-68, 1968:
grades. Functional studies of these genes have given clues to
Akazaki K. Stemmerman G N. Comparative study of latent
their role in prostate cancer or normal prostate biology.
carcinoma of the prostate among Japanese in Japan and
(Debruyne F M. Isaacs W B. Expression of the cellular
Hawaii. Journal of the National Cancer Institute. 50(5) 30 adhesion molecule E-cadherin is reduced or absent in high:1137-44, 1973; Dunn J E. Cancer epidemiology in popugrade prostate cancer. Cancer Research. 52(18):5104--9,
lations of the United States-with emphasis on Hawaii and
1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE.
California-and Japan. Cancer Research. 35(11 Pt.2)
Karthaus H F. Oosterhof G 0 Debruyne F M. Schalken J A
:3240--5, 1975). The findings were that first- and secondDecreased E-cadherin expression is associated with poor
generation Japanese men who migrated to the U.S. have a 35 prognosis in patients with prostate cancer. Cancer Research.
higher prostate cancer incident rate than native Japanese
54(14):3929-33, 1994; metastasis suppressor gene during
men. The emigrant Japanese men's prostate cancer incident
the progression of human prostatic cancer infrequently
rate is similar to that of men in the U.S. Investigating the
involves gene mutation or allelic loss. Cancer Research.
changes of expression in these three classes of cancer56(19):4387-90, 1996 Ueda T. Ichikawa T. Tamaru J.
relevant genes during the course of prostate cancer devel- 40 Mikata A Akakura K. Akimoto S. Imai T. Yoshie 0.
opment will lead to a better understanding of the processes
Shiraishi T. Yatani R. Ito H. Shimazaki J. Expression of the
by which prostate cancels acquire their aggressive potenKAil protein in benign prostatic hyperplasia and prostate
tials. The discovery of molecules whose changes can be
cancer. American Journal of Pathology. 149(5):1435-40,
correlated to the staging of prostate cancer will provide new
1996) while E-cadherin's down-regulation is strongly cortools to improve our ability to better predict the aggressive 45 related to higher Gleason grades (Umbas R. Schalken J A
behaviors of prostate cancer. This approach is now comAalders T W. Carter B S. Karthaus H F. Schaafsma H E.
monly referred to as "molecular staging".
Debruyne F M. Isaacs W B. Expression of the cellular
adhesion molecule E-cadherin is reduced or absent in highDown-regulated genes such as tumor suppressors, invasion suppressors or metastasis suppressors may be used as
grade prostate cancer. Cancer Research. 52(18):5104--9,
prostate cancer markers. Examples of these genes that can 50 1992; Umbas R. Isaacs W B. Bringuier PP. Schaafsma HE.
potentially serve as prostate cancer markers for "molecular
Karthaus HF. Oosterhof G 0. Debruyne FM. Schalken J A
staging" are: KAil (Dong J T. Suzuki H. Pin S S. Bova G
Decreased E-cadherin expression is associated with poor
S., Schalken J A, Issacs W B, Barrett J C. Issace I T.
prognosis in patients with prostate cancer. Cancer Research.
54(14):3929-33, 1994) Functional studies of these genes
Down-regulation of the KAil metastasis suppressor gene
during the progression of human prostatic cancer infre- 55 have given clues to their role in prostate cancer or normal
prostate biology. Human KAI suppress metastasis of rat
quently involves gene mutation or allelic loss. Cancer
Research. 56(19): 4387-90, 1996); (Ueda T, Ichikawa T.,
prostate cancer cells upon gene transfer (Dong J T. Lamb P
W. Rinker-Schaeffer C W. Vukanovic J. Ichikawa T. Isaacs
Tamaru j, Mikata A, Akakura K, Akimoto S, Imai T. Yoshie
0. Shiraishi T. Yatani R. Ito H. Shimazaki J., Expression fof
J T. Barrett J C. KAil, a metastasis suppressor gene for
the KAil protein in benign prostatic hyperplasia and pros- 60 prostate cancer on human chromosome llpll.2 [see
comments]. Science. 268(5212):884-6, 1995). ~ic and p27
tate cancer. American Journal of Pathology 149(5):
1435-40, 1996); E-cadherin (Umbas R. Isaacs W B Brin(kipl) are involved in signaling pathway that inhibits cell
guier PP. Schaafsma H E. Karthaus H F. Oosterhof G 0.
proliferation (Fornaro M. Tallini G. Zheng D Q. Flanagan W
Debruyne FM. Schalken J A Decreased E-Cadherin expresM. Manzotti M. Languino LR. p27(kipl) acts as a downsion is associated with poor prognosis is patients with 65 stream effector of and is coexpressed with the betalC
prostate cancer. Cancer Research. 52(18):5104-9, 1992,
integrin in prostatic adenocarcinoma. Journal of Clinical
Umbas R. Isaacs W B. Bringuier P P. Schaafsma H E.
Investigation. 103(3):321-9, 1999). E-cadherin expression
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is progressively lost during the transformation of rat prostate
(Greenlee R T, Murray T, Bolden S, Wingo PA Cancer
cancer from non-invasive to invasive (Bussemakers M J.
statistics, 1999. Ca: a Cancer Journal for Clinicians
van Moorselaar R J. Giroldi LA Ichikawa T. Isaacs J T.
2000;50:7-33). Breast ductal carcinoma in situ (hereinafter
Takeichi M. Debruyne F M. Schalken J A Decreased
indicated as DCIS) incidence has increased dramatically
expression of E-cadherin in the progression of rat prostatic 5 since 1983 as a result of implementing screening programs
cancer. Cancer Research. 52(10):2916-22, 1992), and it has
(Ernster V L. Barclay J. Increases in ductal carcinoma in situ
also been shown to be an invasion suppressor (Lou W. Krill
(DCIS) of the breast in relation to mammography: a
D. Dhir R. Becich M J. Dong J T. Frierson HF Jr. Isaacs W
dilemma. [Review] [34 refs] Journal of the National Cancer
B. Isaacs J T. Gao AC. Methylation of the CD44 metastasis
Institute. Monographs. (22):151-6, 1997). DCIS is
suppressor gene in human prostate cancer. Cancer Research.
10 described as a malignant growth of epithelial cells within the
59(10):2329-31, 1999). CD44 loss of expression is associducts and lobules of the breast, and is believed to be the
ated with high metastatic ability and transfection of CD44
precursor of all invasive breast carcinoma. DCIS itself is
suppresses metastasis without affecting tumorigenecity of
non-life-threatening; however, current treatment options for
rat prostate cancer cells (Gao AC. Lou W. Dong J T. Isaacs
DCIS include masectomy, lumpectomy, radiotherapy or
J T. CD44 is a metastasis suppressor gene for prostatic
cancer located on human chromosome llp13. Cancer 15 tamoxifen (Ernster V L. Barclay J. Increases in ductal
carcinoma in situ (DCIS) of the breast in relation to mamResearch. 57(5):846-9. 1997). CD44 down-regulation is a
mography: a dilemma. [Review] [34 refs] Journal of the
prognostic marker for prostate cancer (Noordzij M A van
National Cancer Institute. Monographs. (22):151-6, 1997;
Steenbrugge G J. Verkaik NS. Schroder F H. van der Kwast
Hwang ES. Esserman LJ. Management of ductal carcinoma
T H. The prognostic value of CD44 isoforms in prostate
cancer patients treated by radical prostatectomy. Clinical 20 in situ. [Review] [91 refs] Surgical Clinics of North
Cancer Research. 3(5):805-15, 1997).
America. 79(5):1007-30, viii, 1999). These treatment
Human prostate cancer histology is heterogeneous, or
options for DCIS are at best controversial due primarily to
"multi-focal" in nature (Isaacs J T. Bova G S. Prostate
a lack of precision in diagnosis and prognosis of whether the
Cancer. In The Genetic Basis of Human Cancer (Eds.
detected DCIS will progress to invasive breast cancer and
Vogelstein B and Kinzler K W), pp653-60, McGraw-Hill 25 whether recurrence is likely after treatment, usually with a
Health Professions Division, 1998 and Bova, 1998), with an
high percentage being invasive breast cancer (Zaugg K.
average of five lesions in a patient (Bastacky S I. Wojno K
Bodis S. Is there a role for molecular prognostic factors in
J. Walsh P C. Carmichael M J. Epstein J I. Pathological
the clinical management of ductal carcinoma in situ (DCIS)
features of hereditary prostate cancer. Journal of Urology.
of the breast? [Review] [ 49 refs] Radiotherapy & Oncology.
153(3 Pt 2):987-92, 1995). Between the tumor regions of a 30 55(2):95-9, 2000). At present, histological grading (nuclear
prostate and within a single tumor region, the genetic causes
grading and whether come do-type necrosis is present) and
to the cancer are heterogeneous and independent as well
the size of the DCIS are used to provide assessments of risk
(Sakr WA Macoska J A Benson P. Grignon D J. Wolman
of DCIS to progress into invasive breast cancer (Zaugg K.
S R. Pontes J E. Crissman J D. Allelic loss in locally
Bodis S. Is there a role for molecular prognostic factors in
metastatic, multisampled prostate cancer. Cancer Research. 35 the clinical management of ductal carcinoma in situ (DCIS)
54(12):3273-7, 1994; Qian J. Bostwick D G. Takahashi S.
of the breast? [Review] [ 49 refs] Radiotherapy & Oncology.
Borell T J. Herath J F. Lieber M M. Jenkins R B. Chromo55(2):95-9, 2000; Shaker B S. Sloane J P. DCIS grading
somal anomalies in prostatic intraepithelial neoplasia and
schemes and clinical implications. [Review] [ 40 refs] Hiscarcinoma detected by fluorescence in situ hybridization.
topathology. 35(5):393-400, 19; van de Vijver M J. Ductal
Cancer Research. 55(22):5408-14, 1995; Mirchandani D. 40 carcinoma in situ of the breast: histological classification
Zheng J. Miller G J. Ghosh AK. Shibata D K. Cote R J.
and genetic alterations. [Review] [ 69 refs] Recent Results in
Roy-Burman P. Heterogeneity in intra tumor distribution of
Cancer Research. 152:123-34, 1998). These parameters are
p53 mutations in human prostate cancer. American Journal
far from being adequate for making the most accurate choice
of Pathology. 147(1):92-101, 1995). In the end, the best
of treatment, resulting in a choice either overly excessive or
predictor of prostate cancer's potential to gain invasiveness 45 conservative, in either case, the patient will suffer unnecesmay be a consideration of a number of genes whose expressarily. Molecular markers can help improve our ability to
sion levels change along the course of cancer development,
better diagnose DCIS and stratify treatment options, espeas demonstrated in principle by Greene et al. (Greene G F.
cially the molecular markers that, themselves, play a role in
Kitadai Y. Pettaway CA von Eschenbach AC. Buucana C
the progression of DCIS to invasive breast cancer (Zaugg K.
D. Fidler I J. Correlation of metastasis-related gene expres- 50 Bodis S. Is there a role for molecular prognostic factors in
sion with metastatic potential in human prostate carcinoma
the clinical management of ductal carcinoma in situ (DCIS)
cells implanted in nude mice using an in situ messenger
of the breast? [Review] [ 49 refs] Radiotherapy & Oncology.
RNA hybridization technique. American Journal of Pathol55(2):95-9, 2000; Silverstein M J. Masetti R. Hypothesis
ogy. 150(5):1571-82, 1997). Hence, expanding the reperand practice: are there several types of treatment for ductal
tory of such genes, including both the onco-genes and the 55 carcinoma in situ of the breast? [Review] [ 53 refs] Recent
suppressor genes, will enhance the accuracy and dependResults in Cancer Research. 152:105-22, 1998). The tumability of this approach.
origenesis process is a multi-step transformation in which
As for the treatment options of prostate cancer, patients
molecular events escalate to the final stage of invasive
with truly organ-confined prostate cancer can be cured by
phenotype (Silverstein M J. Masetti R. Hypothesis and
radical prostatectomy. Patients with non-organ-confined 60 practice: are there several types of treatment for ductal
prostate cancers, however, have very low survival rates and
carcinoma in situ of the breast? [Review] [ 53 refs] Recent
the current treatments are largely ineffective (Yagoda A
Results in Cancer Research. 152:105-22, 1998). The conPetrylak D. Cytotoxic chemotherapy for advanced hormoneventional paradigm of protease involvement in the develresistant prostate cancer. [Review] [63 refs] Cancer. 71(3
opment and progression of cancer has been the assignment
Suppl):1098-109, 1993).
65 of a usually negative role to the proteases, such as promoting
Breast cancer is the most diagnosed cancer in women and
tumor invasion (Mignatti P. Rifkin D B. Biology and biothe second leading cancer related cause of death in women
chemistry of proteinases in tumor invasion. [Review] [306
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refs] Physiological Reviews. 73(1):161-95, 1993). In turn,
Chao J. Prostasin is a novel human serine proteinase from
seminal fluid. Purification, tissue distribution, and localizathe conventional paradigm of protease inhibitors in relation
tion in prostate gland. Journal of Biological Chemistry.
to cancer is usually regard of a beneficial effect for the
presence of these molecules (Kennedy AR. Chemopreven269(29):18843-8, 1994; (Yu J X. Chao L. Chao J. Molecular
tive agents: protease inhibitors. Pharmacol Therapeut 5 cloning, tissue-specific expression, and cellular localization
78:167-209, 1998). Recently, however, the picture of a new
of human prostasin mRNA. Journal of Biological Chemistry.
paradigm is beginning to emerge for several serine proteases
270(22):13483-9, 1995). Molecular cloning of a full-length
in breast, prostate, and testicular cancers. A "normal epithehuman prostasin cDNA revealed that its predicted amino
lial cell specific-1" (NESl) serine protease was found to be
acid residue sequence contains a carboxyl-terminal hydrodown-regulated in breast and prostate cancers, and it func- 10 phobic region that can potentially anchor the protein on the
tions as a tumor suppressor (Goyal J, Smith KM, Cowan J
membrane (Yu J X Chao L. Chao J. Molecular cloning,
M, Wazer D E, Lee SW, Band V. The role for NESl serine
tissue-specific expression, and cellular localization of
protease as a novel tumor suppressor. Cancer Res
human prostasin mRNA. Journal of Biological Chemistry.
270(22):13483-9, 1995). At the amino acid level, prostasin
58:4782-4786, 1998). A prostate-specific serine protease,
prostase (Nelson P S. Gan L. Ferguson C. Moss P. Gelinas 15 is similar to plasma kallikrein, coagulation factor XI, hepsin,
R. Hood L. Wang K. Molecular cloning and characterization
plasminogen, acrosin, prostase, and, in particular, testisin
of prostase, an androgen-regulated serine protease with
(sharing 44% sequence identity) [Nelson P S. Gan L. Ferprostate-restricted expression. Proceedings of the National
guson C. Moss P. Gelinas R. Hood L. Wang K. Molecular
Academy of Sciences of the United States of America.
cloning and characterization of prostase, an androgen96(6):3114-9, 1999), was shown to be expressed in normal 20 regulated serine protease with prostate-restricted expression.
prostate but not in prostate cancer cell lines DU-145 and
Proceedings of the National Academy of Sciences of the
PC-3. The expression of a testis-specific serine protease,
United States of America. 96(6):3114-9, 1999; Hooper JD.
Nicol D L. Dickinson J L. Eyre HJ. Scarman AL. Normy le
testisin, was shown to be lost in testicular cancer through
either a loss of gene (Hooper JD. Nicol D L. Dickinson J L.
J F. Stuttgen MA Douglas M L. Loveland KA Sutherland
Eyre HJ. ScarmanAL. Normyle J F. Stuttgen MA Douglas 25 G R. Antalis T M. Testisin, a new human serine proteinase
M L. Loveland KA Sutherland G R. Antalis T M. Testisin,
expressed by premeiotic testicular germ cells and lost in
a new human serine proteinase expressed by premeiotic
testicular germ cell tumors. Cancer Research. 59(13)
:3199-205, 1999; Yu J X. Chao L. Chao J. Molecular
testicular germ cells and lost in testicular germ cell tumors.
cloning, tissue-specific expression, and cellular localization
Cancer Research. 59(13):3199-205, 1999) or methylation in
the promoter (Boucaut K, Douglas M, Clements J, Antalis T. 30 of human prostasin mRNA. Journal of Biological Chemistry.
270(22): 13483-9, 1995). A membrane-bound Xenopus kidThe serine proteinase testisin may act as a tumor and/or
ney epithelial cell sodium channel-activating protease
growth suppressor in the testis and may be regulated by
DNA methylation. Cancer Genetics and Tumor Suppressor
(CAPl) was shown to be highly homologous to human
Genes, Cold Spring Harbor Laboratory, 2000). Further,
prostasin as well (sharing 53% sequence identity at the
transfection of human testicular cancer cells with a testisin 35 amino acid level) (Vallet V. Chraibi A Gaeggeler H P.
cDNAreduced the tumor growth of xenografts of these cells
Horisberger JD. Rossier B C. An epithelial serine protease
activates the amiloride-sensitive sodium channel. Nature.
in nude mice, suggesting a tumor suppressor function for
testisin (Boucaut K, Douglas M, Clements J, Antalis T. The
389(6651):607-10, 1997). Prostasin is encoded by a singleserine proteinase testisin may act as a tumor and/or growth
copied gene, which is located on human chromosome
suppressor in the testis and may be regulated by DNA 40 16pll.2 (Yu J X. Chao L. Ward DC. Chao J. Structure and
methylation. Cancer Genetics and Tumor Suppressor Genes,
chromosomal localization of the human prostasin (PRSS8)
gene. Genomics. 32(3):334-40, 1996). The secreted prostaCold Spring Harbor Laboratory, 2000). The testisin serine
protease is potentially membrane-bound as suggested by its
sin cleaves synthetic substrates in vitro preferentially at the
structure and confirmed by immunohistochemistry gene
carboxyl-terminal side ofArg residue, and is thus considered
(Hooper JD. Nicol D L. Dickinson J L. Eyre HJ. Scarman 45 a trypsin-like serine protease (Yu J X. Chao L. Chao J.
AL. Normy le J F. Stuttgen MA Douglas ML. Loveland K
Prostasin is a novel human serine proteinase from seminal
A Sutherland G R. Antalis T M. Testisin, a new human
fluid. Purification, tissue distribution, and localization in
serine proteinase expressed by premeiotic testicular germ
prostate gland. Journal of Biological Chemistry. 269(29)
cells and lost in testicular germ cell tumors. Cancer
:18843-8, 1994). The physiological function of prostasin,
Research. 59(13):3199-205, 1999.) Prostasin serine pro- 50 however, has remained unknown. By comparing gene
tease is an acidic protein (pl 4.5-4.8) of approximately 40
expression of normal tissues, pre-invasive cancer, and invakDa in molecular mass (Yu J X. Chao L. Chao J. Prostasin
sive cancer, it would be highly advantageous to discover
is a novel human serine proteinase from seminal fluid.
molecular markers that display a differential expression
Purification, tissue distribution, and localization in prostate
pattern between the pre-invasive and the invasive phenogland. Journal of Biological Chemistry. 269(29):18843-8, 55 types and use these markers for a more precise diagnosis and
1994). It is predominantly made in the prostate gland (-140
prognosis of prostate and/or breast cancers. With the
ng/mg protein), with lesser amounts (2-6 ng/mg protein)
enhanced precision in diagnosis and prognosis, treatment
also found in the bronchi, colon, kidney, liver, lung,
options for patients with DCIS could then be stratified.
pancreas, and the salivary glands (Yu J X. Chao L. Chao J.
Those with low risks of developing invasive breast cancer
Prostasin is a novel human serine proteinase from seminal 60 will have a higher confidence in choosing breast-conserving
fluid. Purification, tissue distribution, and localization in
options, while those at high risks will ponder more aggresprostate gland. Journal of Biological Chemistry. 269(29)
sive options with the necessary follow-up treatments.
:18843-8, 1994). Prostasin is secreted in the prostatic fluid,
Similarly, those males with low risks of developing invasive
prostate cancer will have a higher confidence in choosing
and can be detected in the semen (-9 µg/ml). Prostasin
expression is localized to the epithelial cells of human 65 prostate-conserving options, while those at high risks will
prostate gland by in situ hybridization histochemistry using
ponder more aggressive options with the necessary followan antibody or an anti-sense RNA probe (Yu J X. Chao L.
up treatments.
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SUMMARY OF THE INVENTION

BRIEF DESCRIPTION OF THE FIGURE

The first objective of the present invention is to reduce
FIG. 1 is a diagrammatic representation of the analysis of
deficiencies in the prior art with specific regard to differenprostasin indicative of the absence or existence, or of the
tial diagnosis of invasive prostate and breast cancers and to
invasiveness of human prostate carcinoma.
5
treatment of invasive and metastatic prostate and breast
FIG. 2 is a diagrammatic representation of the analysis of
cancers.
prostasin indicative of the absence or existence, or of the
The second objective of the present invention is to proinvasiveness of human mammary carcinoma.
vide a new marker for prostate and breast cancer.
FIG. 3 shows human prostasin expression in prostate
The third objective of the invention is to provide as a drug 10 epithelial cells.
to patients with carcinoma of the prostate via delivery of a
FIG. 4A shows immunohistochemical detection of prosfunctional prostasin gene.
tasin protein in benign human prostate tissues.
The fourth objective of the invention is to provide as a
FIG. 4B is an enlarged view of the boxed region of FIG.
drug to patents with carcinoma of the prostate via delivery
4A.
15
of a functional prostasin cDNA.
FIG. 4C shows immunohistochemistry of benign human
The fifth objective of the invention is to provide as a drug
prostate tissues with prostasin antibody omitted in the
to patents with carcinoma of the breast via delivery of a
procedures, no epithelial cells displayed any staining.
functional prostasin gene.
FIG. 4D is an enlarged view of the boxed region of FIG.
The sixth objective of the invention is to provide as a drug
20 4C.
to patents with carcinoma of the breast via delivery of a
FIG. 4E shows immunohistochemistry of human prostate
functional prostasin cDNA.
tumor with prostasin antibody omitted in the procedures, no
This invention identifies prostasin serine protease as a
epithelial cells displayed any staining.
potential marker, and as a tumor invasion suppressor for
FIG. 4F shows immunohistochemical detection of prosprostate and breast cancers and thus provides methods (a),
25 tasin protein in benign human prostate tissue surrounded by
(b), and (c) of determining invasiveness levels of human
prostate carcinomas.
carcmomas:
FIG. 4G shows immunohistochemical detection of pros(a) using prostasin protein levels, comprising the steps of:
tasin protein in Gleason grade 2 prostate tumor.
sampling a human carcinoma tissue; determining prosFIG. 4H is an enlarged view of the boxed region of FIG.
tasin protein levels in the human carcinoma tissue; 30
4G.
preferably by applying an immunological reagentFIG. 4I shows immunohistochemical detection of prostaantibody to said tissue wherein the reagent-antibody
sin protein in Gleason grade 3 prostate tumor.
becomes bound to prostasin protein in said tissue, and
determining invasiveness of the human carcinoma tisFIG. 41 is an enlarged view of the boxed region of FIG.
sue based on the prostasin protein levels; or
35 41.
(b) using prostasin mRNA levels, comprising the steps of:
FIG. 4K shows immunohistochemical detection of prossampling a human carcinoma tissue; determining prostasin protein in Gleason grade 4 prostate tumor.
tasin mRNA levels in the human carcinoma tissue
FIG. 4L is an enlarged view of the boxed region of FIG.
preferably by applying prostasin-specific anti-sense
4K.
RNA probes in an in situ hybridization to determine the 40
FIG. 5 shows human prostasin expression in human breast
prostasin mRNA levels in the separated human carcicancer cell lines.
noma tissue the determination of the prostasin mRNA
FIG. 6 shows promoter hypermethylation of the human
levels in the separated human carcinoma sample tissue;
prostasin
gene in human prostate and breast cancer cell lines.
to make possible and determining invasiveness of the
FIG. 7 shows prostasin protein expression and in vitro
human carcinoma tissue based on the prostasin mRNA 45
invasive properties of the DU-145 and the PC-3 transfeclevels; or
tants.
(c) (c) using prostasin gene promoter DNA methylation
FIG. 8 shows prostasin protein expression and in vitro
levels, comprising the steps of: sampling a human
invasive properties of the MDA-MB-231 and the MDAcarcinoma tissue; determining prostasin gene promoter
DNA methylation levels in the human carcinoma 50 MB-435s transfectants.
tissue, preferably by applying prostasin-promoterDESCRIPTION OF THE PREFERRED
specific oligonucleotide primers in a PCR to determine
EMBODIMENT
the prostasin gene promoter DNAmethylation levels in
Before explaining the disclosed embodiment of the
the sampled human carcinoma tissue and determining
invasiveness of the human carcinoma tissue based on 55 present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
the prostasin gene promoter DNA methylation levels,
particular arrangement shown since the invention is capable
as well as a method of treating invasive human carcinomas
of other embodiments. Also, the terminology used herein is
comprising the steps of: incorporating human prostasin
for the purpose of description and not of limitation.
nucleic acid into a selected gene delivery vector nucleic acid
to form a recombinant nucleic acid; preferably wherein the 60
Using RT-PCR and western blot analyses, prostasin pronucleic acid includes a gene or cDNA delivering the recomtein and mRNA expression were found in normal human
binant nucleic acid into a human carcinoma; and reducing
prostate epithelial cells and the human prostate cancer cell
invasiveness of the human carcinoma.
line LNCaP, but discovered not present in the highly invasive human prostate cancer cell lines DU-145 and PC-3.
Further objects and advantages of this invention will be
apparent from the following detailed description of a pres- 65 Immunohistochemistry studies of human prostate cancer
ently preferred embodiment, which is illustrated schematispecimens revealed a down-regulation of prostasin in highcally in the accompanying drawings.
grade tumors.
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Using RT-PCR and western blot analyses, prostasin proRefer now to FIG. 3 which shows human prostasin
tein and mRNA expression were found in a non-invasive
expression in prostate epithelial cells. By means of western
human breast cancer cell line, MCF-7, while invasive human
blot analysis (upper panel), prostasin (as a 40-kDa band) was
breast cancer cell lines MDA-MB-231 and MDA-MB-435s
detected in normal human prostate epithelial cells (CCwere also discovered not to express either the prostasin 5 2555) and the LNCaP cells, but not in the DU-145 or PC-3
protein or the mRNA. A non-invasive human breast cancer
cells. An equal amount of total protein (100 µg) was loaded
cell line. MDA-MB-453, was shown to express prostasin
for each sample. At the mRNA level, human prostasin
mRNA but not prostasin protein. Examination of the prosmRNA (via a 232-bp amplified DNA band) was detected in
tasin gene promoter in the human prostate and breast cancer
normal prostate epithelial cells (CC-2555) and the LNCaP
cell lines by Southern blot analysis revealed heterogeneous
10 cells, but not in the DU145 or PC-3 cells as analyzed by
methylation of the promoter in DU-145, PC-3 and MDART-PCR/Southern blot hybridization (middle panel).
MB-453 cells, and homogeneous methylation of the proCo-amplification of a 556-bp human ~-actin message (as
moter in MDA-MB-231 and MDA-MB-435s cells. The
shown in the gel photograph in the lower panel) confirmed
prostasin gene promoter in normal human prostate epithelial
the quality and the quantity of the RNA applied in each
cells, the LNCaP and the prostasin gene promoter in the
RT-PCR.
human prostate and breast cancer cell lines by Southern blot 15
Expression of prostasin protein is reduced in high-grade
analysis revealed heterogeneous methylation of the prohuman prostate tumor. Prostatectomy specimens from 39
moter in DU-145, PC-3 and MDA-MB-453 cells, and homopatients (128 sections) were subjected to immunohistochemgeneous methylation of the promoter in MDA-MB-231 and
istry using a prostasin-specific antibody. Overall, in nonMDA-MB-435s cells. The prostasin gene promoter in normal human prostate epithelial cells, the LNCaP and the 20 tumor or benign prostate epithelia, 89.0% of the examined
areas demonstrated positive staining for prostasin protein
MCF-7 cells was shown to be unmethylated. Transfection of
and 11.0% were considered negative (based on the scoring
DU-145 and PC-3 cells with a full-length human prostasin
system used for HercepTest™, DAKO Corporation,
cDNArestored prostasin expression and reduced the in vitro
invasiveness by 68% and 42%, respectively. Transfection of
Carpinteria, Calif.). In all tumor specimens that were
MDA-MB-231 and MDA-MB-435s cells with a full-length 25 examined, prostasin was detected in 93.3% of the low
human prostasin cDNA restored prostasin expression and
Gleason grade areas (~grade 2), 44.4% of Gleason grade 3
reduced the in vitro invasiveness by 50% for either cell line.
areas, 21.1 % of Gleason grade 4 areas, but not in Gleason
Cell proliferation was unaffected by re-expression of prosgrade 5 areas (data summarized in Table 1). The mean
tasin. Our data indicate that prostasin is implicated in normal
prostasin immunostaining score was found significantly
prostate biology and its down-regulation in prostate cancer, 30 decreased in high-grade prostate tumors as compared to
and its absence in invasive prostate and breast cancer cell
non-tumor areas (ANOVA, p<0.0001).
lines indicates increased invasiveness. Our results also indiRepresentative staining images of non-tumor (benign)
cate that delivering a functional human prostasin gene to
areas and prostate tumor areas are shown in FIGS. 4a-4l,
invasive prostate and breast cancers can reduce the invawhich provides immunohistochemical detection of prostasin
siveness.
35 protein in tissues. Paraffin-embedded human prostate secFor a facile understanding of the invention embodied
tions were stained for prostasin protein expression evaluaherein, reference should now be made to FIGS. 1and2. FIG.
tion using a specific antibody as described (Yu J X. Chao L.
1 sets forth a schematic for determining if a male has
Chao J. Prostasin is a novel human serine proteinase from
prostate cancer. Human blood 10 is taken from the male and
seminal fluid. Purification, tissue distribution, and localizaanalyzed for the presence of prostasin serine protease 14. If 40 tion in prostate gland. Journal of Biological Chemistry.
NO 12 prostasin is found, there is probably little or no
269(29):18843-8, 1994). Prostasin positive staining (brown
cancer. If there is a presence YES 16 of prostasin serine
color) was detected in the cytoplasm and apical membrane
protease 14, there is prostate cancer.
in non-tumor or benign epithelial cells.
If a biopsy of the prostate gland 20 is analyzed for the
The prostasin protein was detected in the cytoplasm and
presence of a normal amount YES 22 of prostasin serine 45 on the plasma membrane (apical) of benign epithelial cells
protease 14, there is no cancer or there is non-invasive
lining the secretory lumen as well as in the secretion inside
cancer. If there is NO 24 or Reduced 26 amount of prostasin
the lumen (FIGS. 4A and 4B, score 3, or+++), confirming
serine protease 14, there is invasive cancer.
the results of (Yu J X. Chao L. Chao J. Prostasin is a novel
FIG. 2 sets forth a schematic for determining if a female
human serine proteinase from seminal fluid. Purification,
has breast cancer. Human blood 100 is taken from the female 50 tissue distribution, and localization in prostate gland. Journal
and analyzed for the presence of prostasin serine protease
of Biological Chemistry. 269(29):18843-8, 1994). When a
140. If NO 120 prostasin is found, there is prospectively no
pre-immune rabbit serum was used in place of the prostasin
cancer. If there is a presence YES 160 of prostasin serine
antiserum, no staining was observed in either the non-tumor
protease 140, there is breast cancer. It a biopsy of the breast
epithelia (FIGS. 4C and 4D) or tumor epithelia (FIG. 4E).
200 is analyzed for the presence of YES 220 of prostasin 55 Tumor epithelia displayed various degrees of prostasin
serine protease 140, there is no invasive cancer but may be
immunostaining as shown in FIGS. 4F-4L. In Gleason grade
non-invasive cancer. If there is NO 240 or Reduced 260
1-2 tumors, moderate prostasin staining is seen in the
amount of prostasin serine protease 140, there is invasive
cytoplasm and on the plasma membrane of some epithelial
cancer.
cells, as well as in the secretion in the lumen (FIGS. 4G and
The levels of prostasin protein in the epithelial cells of the 60 4H, score 2, or ++ ). In Gleason grade 3 tumors, a lesser
human prostate and can be used as a diagnostic marker for
number of epithelial cells displayed the moderate level
prostasin staining (FIGS. 4I and 41). In Gleason grade 4
the potential invasiveness of prostate tumors. The supporting evidence came from our findings that two invasive
tumors, most epithelial cells did not show any prostasin
human prostate cancer cell lines DU-145 and PC-3 do not
staining, while some prostasin staining can be seen in rare,
express prostasin while normal prostate epithelial cells and 65 sporadic tumor cells (FIGS. 4K and 4L, as indicated by the
a non-invasive prostate cancer cell line LNCaP express both
arrow, score 0). Genetically, prostate tumors are heterogeneous and multi-focal in nature, in that one patient's grossthe prostasin mRNA and protein.
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anatomy tumor comes from multiple initial lesions which
prostasin promoter in these cells. For DU-145, PC-3, and
MDA-MB-453 DNA, both the 1,052-bp and the 1,275-bp
are caused by different initial transformation events and
progress to different stages by different ensuing transformafragments are generated in the methylation-sensitive
tions (Isaacs J T. Bova GS. Prostate Cancer. In The Genetic
digestion, suggesting incomplete methylation (one of two or
Basis of Human Cancer (Eds. Vogelstein B and Kinzler K 5 more chromosomes) or clonal methylation in a subpopulation of cells. For the MDA-MB-231 and MDA-MBW), pp653-60. McGraw-Hill Health Professions Division,
1998). The Gleason grading, when used as a percentage of
435, however, the Hpa II digestion did not yield the 1,052-bp
but rather gave the 1,275-bp fragment. This homogeneous
each cancer occupied by Gleason grade 4/5 areas, is indemethylation pattern indicates that the Msp I/Hpa II site, at
pendently associated with prostate cancer progression
(Stamey T A, McNeal J E, Yemoto C M, Sigal B M, 10 location -95 (relative to the transcription initiation site) of
the prostasin promoter, is methylated (hypermethylated) in
Johnstone I M. Biological determinants of cancer progresthese DNA samples. Signal intensity variation may be
sion in men with prostate cancer. JAMA 281: 1395-1400,
attributed to aneuploidy.
1999). We found a significant decrease of prostasin expresAn examination of the prostasin gene promoter region for
sion in the high-grade, i.e., the more progressively transDNA methylation differences among human prostate and
formed tumors.
15 breast cancer cell lines has been made. (see FIG. 6). We
As earlier indicated, FIG. 5 shows human prostasin
found that cells that express prostasin, normal prostate
expression in human breast cancer cell lines. By means of
epithelial, LNCaP, and MCF-7, are unmethylated in the
western blot analysis (upper panel), prostasin (as a 40-kDa
prostasin promoter while MDA-MB-453 showed heterogeband) was detected in MCF-7 cells, but not in MDA-MBneous prostasin promoter methylation. For cells that do not
453, MDA-MB-231, or MDA-MB-435s cells. An equal 20 express prostasin, DU-145 and PC-3 showed heterogeneous
amount of total protein (100 µg) was loaded for each sample.
prostasin promoter methylation while MDA-MB-231 and
At the mRNA level, human prostasin mRNA (via a 232-bp
MDA-MB-435 showed homogeneous hypermethylation in
amplified DNA band) was detected in MCF-7 and MDAthe promoter region of the prostasin gene.
MB-453 cells, but not in the MDA-MB-231 or MDA-MBTwo human prostate cancer cell lines that do not express
435s cells as analyzed by RT-PCR/Southern blot hybridiza- 25 prostasin, the highly invasive DU-145 and PC-3, show
tion (lower panel).
heterogeneous methylation in the promoter region of the
prostasin gene. The result suggests that at least one of the
Prostasin mRNAexpression is seen absent in two invasive
two (or more) chromosome 16's of these cell lines is
human breast cancer cell lines while two non-invasive breast
methylated at the prostasin gene locus. The prostasin gene
cancer cell lines express prostasin mRNA or protein. Analysis of prostasin expression in human breast cancer cell lines 30 on the unmethylated chromosome may contain mutations
that silenced the expression. An alternative explanation for
showed that the non-invasive MCF-7 and MDA-MB-453
the heterogeneous methylation pattern is that the methylacells express the prostasin mRNA while the highly invasive
tion occurs in clonal cell populations, however, the lack of
MDA-MB-231 and MDA-MB-435s cells do not express the
detectable prostasin mRNA in our RT-PCR-Southern blot
prostasin mRNA (see FIG. 5). Expression of prostasin
mRNA in normal human breast can be demonstrated by the 35 analysis in the DU-145 and PC-3 cells argues against this
possibility.
presence of two GenBank™ normal human breast EST
The significance of the finding on prostasin gene promoter
sequences coding for prostasin (Accession numbers
hypermethylation in prostate or breast cancer is that the
R48653, and R48557). The MCF-7 cells also express the
measurement of prostasin down-regulation as a cancer
prostasin protein as determined by western blot analysis
(again see FIG. 5).
40 marker may be achieved by using a binary assay (yes-or-no),
instead of a gradually decreasing quantity in the immunoProstasin down-regulation in prostate or breast cancer can
histochemistry assay (which is quite arbitrary).
be caused by promoter methylation or gene-specific mutaRe-expression of human prostasin protein in invasive
tion. Prostasin expression decreases with increasing prostate
human prostate and breast cancer cells reduces invasiveness
cancer grade and is absent in invasive prostate and breast
cancer cell lines. The chromosomal locus where the human 45 in vitro. At this point, reference should be made to FIG. 7
which shows the prostasin protein expression and in vitro
prostasin gene is, 16pll.2, however, is not known to be an
invasive properties of the DU-145 and the PC-3 transfecLOH hot-spot in prostate cancer or in breast cancer. Epigetants. DU-145 or PC-3 cells transfected with either a vector
netic events (such as DNA methylation) may be an alternaDNA (labeled as "vector") or a prostasin cDNA construct
tive mechanism of loss of expression for tumor suppressors
or invasion suppressors. Refer now to FIG. 6 which shows 50 (labeled as "prostasin") were analyzed by a western blot
analysis using a prostasin-specific antibody (upper panel) or
promoter hypermethylation of the human prostasin gene in
subjected to an in vitro Matrigel chemoinvasion assay
human prostate and breast cancer cell lines. Genomic DNA
(lower panel) as described in (Liu D F. Rabbani S A
( 5 µg) from the various cell lines (as indicated in the figure)
Induction of urinary plasmiinogen activator by retinoic acid
were digested with the following restriction enzyme combinations. Xho l/BamH I (X/B, flanking cuts of the 55 results in increased invasiveness of human prostate cancer
cells PC-3. Prostate. 27(5):169-76, 1995). The expressed
methylation-sensitive site), Xho I/BamH I/Msp I (X/B/M),
human prostasin protein (a 40-kDa band) was detected in the
or Xho l/BamH l/Hpa II (X/B/H). The digests were resolved
prostasin cDNA-transfected DU-145 or PC-3 cells, but not
in a 0.8% agarose gel and transferred to an Immobilon-N
in the vector-transfected cells. In the Matrigel chemoinvamembrane for hybridization with a nick-translated prostasin
promoter probe (bases 703-1469 of the prostasin gene 60 sion assay, the vector-transfected cells are expressed as
being 100% invasive (solid bar), the open bar represents the
sequence U33446). The probe detects a promoter fragment
relative invasiveness of the human prostasin cDNAof 1,275 bp, which is cut by the methylation-insensitive
transfected cells. The data were analyzed by a Student t-test
enzyme Msp I to yield a 1,052-bp fragment for all DNA
using the StatView software (Abacus Concepts, Inc.,
samples. The methylation-sensitive isoschizomer Hpa II
yields the 1,052-bp fragment in the CC-2555 (normal pros- 65 Berkeley, Calif.).
It can be seen that Polyclonal DU-145 and PC-3 cells
tate epithelial cells), the LNCaP, and the MCF-7 samples,
transfected with the human prostasin cDNA (designated
indicating the hypomethylated or unmethylated state of the
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intrinsic limitation that the "positive" identifications are not
DU-145/Pro, and PC-3/Pro, respectively) were confirmed to
express the human prostasin protein, as shown in the western
always confirmed for the "diagnosed" disease. Biopsy is still
blot analysis of the cell lysate (FIG. 7, upper panel). The
required for a true positive identification of prostate cancer
vector-transfected cells, designated DU-145/Vector or PC-3/
even in the case of the application of the PSA prostate cancer
Vector, respectively, were used as negative control in the 5 marker (Catalana W J. Partin AW. Slawin KM. Brawer M
western blot. A further examination of the DU-145/Pro and
K. Flanigan R C. Patel A Richie J P. deKernion J B. Walsh
the PC-3/Pro cells by immunocytochemistry confirmed that
P C. Scardino P T. Lange P H. Subong E N. Parson R E.
100% of the cells expressed the prostasin protein (data not
Gasior G H. Loveland K G. Southwick P C. Use of the
shown). In in vitro Matrigel chemoinvasion assays (FIG. 7,
percentage of free prostate-specific antigen to enhance diflower panel), the invasiveness of DU-145/Pro cells was 10 ferentiation of prostate cancer from benign prostatic disease:
determined to be at 32% of that or DU-145 Vector cells (or,
a prospective multicenter clinical trial [see comments].
the reduction of invasiveness was at 68%). The invasiveness
JAMA 279(19):1542-7, 1998). As stated above, it has been
of PC-3/Pro cells was determined to be at 58% of that of
demonstrated in principle that many markers used in a
PC-3Nector cells (or, the reduction of invasiveness was at
multivariate approach may provide a highly accurate diag42%). We performed in vitro cell proliferation assays on 15 nosis (Greene G F. Kitadai Y. Pettaway CA von Eschenbach
DU-145/Pro vs. DU-145Nector cells, and on PC-3/Pro vs.
A C. Bucana C D. Fidler I J. Correlation of metastasisPC-3/Vector cells, but did not observe any difference
related gene expression with metastatic potential in human
between the growth rates of the prostasin cDNA-transfected
prostate carcinoma cells implanted in nude mice using an in
or the vector-transfected cells over an 8-day period (data not
situ messenger RNA hybridization technique. American
shown).
20 Journal of Pathology. 150(5):1571-82, 1997). From the
Forced re-expression of human prostasin in two invasive
standpoint of prostate cancer genetics, the multivariate
human breast cancer cell lines reduced invasiveness. A
approach is well supported by our current understanding. A
full-length human prostasin cDNA under the control of an
serine protease structurally and genetically related to the
RSV promoter was transfected into the invasive breast
PSA, the hK2 (human glandular kallikrein 2) has shown
cancer MDA-MB-231 and MDA-MB-435 cells. Reference 25 some promise of joining the list of markers applicable for
should be made to FIG. 8 which shows prostasin protein
prostate cancer diagnosis (Saedi M S. Hill T M. Kuusexpression and in vitro invasive properties of the MDAReichel K. Kumar A Payne J. Mikolajczyk SD. Wolfert R
MB-231 and the MDA-MB-435s transfectants. MDA-MBL. Rittenhouse H G. The precursor form of the human
231 and MDA-MB-435s cells transfected with either a
kallikrein 2, a kallikrein homologous to prostate-specific
vector DNA (labeled as "vector") or a prostasin cDNA 30 antigen, is present in human sera and is increased in prostate
construct (labeled as "prostasin") were analyzed by a westcancer and benign prostatic hyperplasia. Clinical Chemistry.
ern blot analysis using a prostasin-specific antibody (upper
44(10):2115-9, 1998). Structurally and in prostate gland
panel) or subjected to an in vitro Matrigel chemoinvasion
biology, prostasin shares many common characteristics with
assay (lower panel) as referenced in (Liu D F. Rabbani S A
both PSA and hK2, as being a secreted serine protease made
Induction of urinary plasminogen activator by retinoic acid 35 in large abundance in prostate epithelial cells (Yu J X. Chao
results in increased invasiveness of human prostate cancer
L. Chao J. Prostasin is a novel human serine proteinase from
cells PC-3. Prostate. 27(5):269-76, 1995). The expressed
seminal fluid. Purification, tissue distribution, and localizahuman prostasin protein (a 40-kDa band) was detected in the
tion in prostate gland. Journal of Biological Chemistry.
prostasin cDNA-transfected MDA-MB-231 and MDA-MB269(29):18843-8, 1994; Yu J X. Chao L. Chao J. Molecular
435s cells, but not in the vector-transfected cells. In the 40 cloning, tissue-specific expression, and cellular localization
Matrigel chemoinvasion assay, the vector-transfected cells
of human prostasin mRNA Journal of Biological Chemistry.
are expressed as being 100% invasive (solid bar), the open
270(22):13483-9, 1995). While high-grade prostate cancer
bar represents the relative invasiveness of the human proscells produce less PSA protein than normal prostate cells or
tasin cDNA-transfected cells. The data were analyzed by a
low-grade prostate cancer cells (Hakalahti L. Vihko P.
Student t-test using the StatView software (Abacus 45 Henttu P. Autio-Harmainen H. Saini Y. Vihko R. Evaluation
Concepts, Inc., Berkeley, Calif.).
of PAP and PSAgene expression in prostatic hyperplasia and
Stable, polyclonal, episomal transfectants were obtained
prostatic carcinoma using northern-blot analyses, in situ
and the expression of human prostasin protein was conhybridization and immunohistochemical stainings with
firmed by western blot analysis (FIG. 8, upper panel). In in
monoclonal and bispecific antibodies. International Journal
vitro Matrigel chemoinvasion assays, the invasiveness of 50 of Cancer. 55(4):590-7, 1; Sakai H. Yogi Y. Minami Y.
either cell lines expressing human prostasin was reduced by
Yushita Y. Kanetake H. Saito Y. Prostate specific antigen and
50% as compared to the vector-transfected controls (FIG. 8,
prostatic acid phosphatase immunoreactivity as prognostic;
lower panel).
Sakai H. Yogi Y. Minami Y. Yushita Y. Kanetake H. Saito Y.
Taken together, the foregoing evidences linking prostasin
Prostate specific antigen and prostatic acid phosphatase
level reduction or protasin absence to the invasiveness of 55 immunoreactivity as prognostic), the serum PSA levels in
prostate and breast cancer cell lines, or linking prostasin
prostate cancer patients increase due to tissue damage
expression to reduced invasiveness. The evidence qualifies
caused by invasive cancer (Rittenhouse H G. Finlay J A
prostasin as an invasion suppressor, which thus is a marker
Mikolajczyk SD. ParinA W. Human Kallikrein 2 (hK2) and
for diagnosis of invasiveness of prostate and breast cancers,
prostate-specific antigen (PSA): two closely related, but
or as a therapeutic agent to treat invasive prostate and breast 60 distinct, kallikreins in the prostate. [Review] [ 457 refs]
cancers.
Critical Reviews in Clinical Laboratory Sciences. 35(4)
:275-368, 1998). By comparison, we also believe prostasin
Pathological grading by the Gleason system is performed
is in the circulation of prostate cancer patients. As a result,
after either surgery or biopsy, both highly invasive
a blood test for the circulating prostasin to indicate the
procedures, while blood tests such as that for the PSA
prostate cancer marker can offer the hope of accurate diag- 65 presence and/or the stage of prostate cancer would be highly
nosis and prognosis without the harm of an invasive proceuseful. (as illustrated in FIG. 1). In principal, the feasibility
of a blood test based on prostasin detection to indicate
dure. In practice, however, single markers suffer from an
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cancer has been demonstrated by Berteau et al. (1999).
These authors (Berteau P. Laribi Eschwege P. Lebars I.
Dumas F. Benoit G. Lorie S. Prostasin mRNA to detect
prostate cells in blood of cancer patients. Clinical and
Chemical Laboratory Medicine 37 (SS): S119, 1999), demonstrated a highly promising potential of using prostasin as
a marker to detect circulating prostate epithelial cells, a sign
of prostate tissue damage caused by invasive prostate cancer
leading to the dissemination of prostate epithelial cells into
the circulation. It is expected that a blood test for circulating
prostasin to indicate the presence and/or the stage of breast
cancer would be highly useful. (as illustrated in FIG. 2).
In summary of the invention, it has been taught herein
that: protein prostasin as well as its MRA levels and its gene
promoter DNA methylation levels can be used to determine
the invasiveness level of human carcinomas; and, provide a
method of treating invasive human carcinomas by delivery
thereto of a recombinant nucleic acid formed by a human
prostasin nucleic acid incorporated into a selected gene
delivery vector. Those teachings are repeated for emphasis
in the following:
1. Immunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin
in high-grade tumors.
2. Using RT-PCR and western blot analyses, prostasin
protein and mRNA expression were found in a noninvasive human breast cancer cell line, MCF-7, while
invasive human breast cancer cell lines MDA-MB-231
and MDA-MB-435s were found not to express either
the prostasin protein or the mRNA. A non-invasive
human breast cancer cell line, MDA-MB-453, was
shown to express prostasin mRNA but not prostasin
protein; and,
3. Examination of the prostasin gene promoter in the
human prostate and breast cancer cell lines by Southern
blot analysis revealed heterogeneous methylation of the
promoter in DU-145, PC-3 and MDA-MB-453 cells,
and homogeneous methylation of the promoter in
MDA-MB-231 and MDA-MB-435s cells. The prostasin gene promoter in normal human prostate epithelial
cells, the LNCaP and the MCF-7 cells was shown to be
unmethylated. Transfection of DU-145 and PC-3 cells
with a full-length human prostasin cDNA restored
prostasin expression and reduced the in vitro invasiveness by 68% and 42%, respectively. Transfection of
MDA-MB-231 and MDA-MB-435s cells with a fulllength human prostasin cDNA restored prostasin

expression and reduced the in vitro invasiveness by
50% for either cell line.
The preferred methods of separating sampled human
carcinoma tissue from neighboring normal tissues is by laser
capture micro-dissection.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A method of determining human prostate carcinomas
non-invasiveness using prostasin protein levels, comprising
the steps of:
sampling a human prostate carcinoma tissue
determining prostasin protein levels in the human prostate
carcinoma tissue; and
determining the sampled human prostate carcinoma tissue
is not invasive based on the presence of prostasin
protein.
2. The method of determining human prostate carcinomas
non-invasiveness of claim 1, wherein the step of determining prostasin protein levels includes the step of:
applying an immunological reagent-antibody to the
sampled human prostate carcinoma tissue, wherein the
reagent-antibody becomes bound to prostasin protein in
the sampled human prostate carcinoma tissue.
3. A method of determining human breast carcinomas
non-invasiveness using prostasin protein levels, comprising
the steps of:
sampling a human breast carcinoma tissue
determining prostasin protein levels in the sampled
human breast carcinoma tissue; and
determining the sampled human breast carcinoma tissue is
not invasive based on the presence of prostasin protein.
4. The method of determining human breast carcinomas
non-invasiveness of claim 3, wherein the step of determining prostasin protein levels includes:
applying an immunological reagent-antibody to the
sampled human carcinoma tissue, wherein the reagentantibody becomes bound to prostasin protein in the
sampled human breast carcinoma tissue.
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